Bishop, Michael R., Maziarz, Richard T., Waller, Edmund K. ORCID: 0000-0003-0816-6729, Jaeger, Ulrich, Westin, Jason R., McGuirk, Joseph P., Fleury, Isabelle, Holte, Harald ORCID: 0000-0001-9799-9428, Borchmann, Peter, del Corral, Christopher, Tiwari, Ranjan, Anak, Oezlem, Awasthi, Rakesh, Pacaud, Lida, Romanov, Vadim V. and Schuster, Stephen J. (2019). Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion. Blood Adv., 3 (14). S. 2230 - 2237. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 2473-9537

Full text not available from this repository.

Abstract

Tisagenlecleucel demonstrated high rates of durable responses in adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) in the JULIET trial. Most patients (92%) received bridging therapies to control disease after study entry and before tisagenlecleucel infusion. Here, we examine the efficacy and safety of tisagenlecleucel in the subset of 7 patients who achieved complete response (CR) after bridging therapy and before tisagenlecleucel infusion. Tisagenlecleucel rapidly expanded in all 7 patients, and the transgene levels were measurable for up to 2 years after infusion. After infusion, all 7 patients were still in CR at the month 3 evaluation, and 5 of 7 patients remained progressionfree >12 months. Adverse events were similar to the overall JULIET population. Cytokine release syndrome (CRS) was reported in 4 of 7 patients (grade 2 = 2 and grade 3 = 2 using the Penn grading scale), and 1 patient experienced grade 1 neurotoxicity. No patient required tocilizumab or steroids for CRS management. These data provide preliminary evidence of tisagenlecleucel efficacy in patients with r/r DLBCL without detectable disease after bridging or salvage therapies and warrant further investigation of tisagenlecleucel as consolidative therapy in future trials.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Bishop, Michael R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Maziarz, Richard T.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Waller, Edmund K.UNSPECIFIEDorcid.org/0000-0003-0816-6729UNSPECIFIED
Jaeger, UlrichUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Westin, Jason R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
McGuirk, Joseph P.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fleury, IsabelleUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Holte, HaraldUNSPECIFIEDorcid.org/0000-0001-9799-9428UNSPECIFIED
Borchmann, PeterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
del Corral, ChristopherUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Tiwari, RanjanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Anak, OezlemUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Awasthi, RakeshUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Pacaud, LidaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Romanov, Vadim V.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schuster, Stephen J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-134784
DOI: 10.1182/bloodadvances.2019000151
Journal or Publication Title: Blood Adv.
Volume: 3
Number: 14
Page Range: S. 2230 - 2237
Date: 2019
Publisher: AMER SOC HEMATOLOGY
Place of Publication: WASHINGTON
ISSN: 2473-9537
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
HematologyMultiple languages
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/13478

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item